NEW YORK (GenomeWeb News) – Vermillion today announced a $16.4 million offering of common stock.

The Austin, Texas-based diagnostics firm is offering 8,350,000 shares of common stock at $1.96 per share. The company has also granted the underwriters a 30-day option to purchase up to an additional 1,252,500 shares to cover over-allotments. Net proceeds after deducting expenses are expected to be roughly $15.2 million.

The offering is expected to close on or about July 17.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.

Nov
15
Sponsored by
Twist Bioscience

This webinar will discuss how Amyris, a biotechnology company that develops renewable products for a broad range of applications and industries, uses large-scale microbial engineering to support its manufacturing processes.

Dec
03
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.